Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma
Author: Hutson, T.
Escudier, B.
Esteban, E.
Bjarnason, G.
Lim, H.
Pittman, K.
Senico, P.
Niethammer, A.
Lu, D.
Hariharan, S.
Motzer, R.
Citation: Journal of Clinical Oncology, 2014; 32(8):760-767
Publisher: American Society of Clinical Oncology
Issue Date: 2014
ISSN: 0732-183X
Statement of
Thomas E. Hutson, Bernard Escudier, Emilio Esteban, Georg A. Bjarnason, Ho Yeong Lim, Kenneth B. Pittman, Peggy Senico, Andreas Niethammer, Dongrui Ray Lu, Subramanian Hariharan, and Robert J. Motzer
Abstract: Abstract not available
Keywords: Humans
Description: Published online before print December 2, 2013
Rights: © 2013 by American Society of Clinical Oncology
DOI: 10.1200/JCO.2013.50.3961
Published version:
Appears in Collections:Aurora harvest 3
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.